Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy

We herein report a 63-year-old woman with small-cell lung cancer (SCLC) who developed dermatomyositis (DM) after initial chemoradiotherapy despite tumor reduction. Serum anti-transcriptional in termediary factor (TIF) 1γ antibody was detected before the development of DM, and its levels increased ov...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2019/02/01, Vol.58(3), pp.427-431
Main Authors: Aritomi, Takafumi, Kido, Takashi, Nakano, Kazuhisa, Satoh, Yurie, Noguchi, Shingo, Jotatsu, Takanobu, Hanaka, Tetsuya, Satoh, Minoru, Tanaka, Yoshiya, Yatera, Kazuhiro
Format: Article
Language:English
Subjects:
anti-transcriptional intermediary factor 1 γ antibody
autoantibody
Case Report
Chemoradiotherapy
Dermatomyositis
Internal medicine
Lung cancer
Small cell lung carcinoma
small-cell lung cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We herein report a 63-year-old woman with small-cell lung cancer (SCLC) who developed dermatomyositis (DM) after initial chemoradiotherapy despite tumor reduction. Serum anti-transcriptional in termediary factor (TIF) 1γ antibody was detected before the development of DM, and its levels increased over time. She died five months after the diagnosis of SCLC. Anti-TIF1γ antibody is known to be a marker for cancer-associated DM (CAM); however, the present case indicates that the antibody can be found in cancer patients without DM. This case is also unusual, as DM developed later despite successful chemoradiotherapy.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.1007-18